ATE524445T1 - Benzocycloheptapyridine als inhibitoren der tyrosinkinase met - Google Patents
Benzocycloheptapyridine als inhibitoren der tyrosinkinase metInfo
- Publication number
- ATE524445T1 ATE524445T1 AT06785313T AT06785313T ATE524445T1 AT E524445 T1 ATE524445 T1 AT E524445T1 AT 06785313 T AT06785313 T AT 06785313T AT 06785313 T AT06785313 T AT 06785313T AT E524445 T1 ATE524445 T1 AT E524445T1
- Authority
- AT
- Austria
- Prior art keywords
- tyrosine kinase
- benzocycloheptapyridines
- inhibitors
- kinase met
- met
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69322905P | 2005-06-23 | 2005-06-23 | |
US72906105P | 2005-10-21 | 2005-10-21 | |
PCT/US2006/024247 WO2007002254A2 (en) | 2005-06-23 | 2006-06-22 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE524445T1 true ATE524445T1 (de) | 2011-09-15 |
Family
ID=37478833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06785313T ATE524445T1 (de) | 2005-06-23 | 2006-06-22 | Benzocycloheptapyridine als inhibitoren der tyrosinkinase met |
Country Status (11)
Country | Link |
---|---|
US (2) | US8207186B2 (de) |
EP (1) | EP1896421B1 (de) |
JP (2) | JP4119478B1 (de) |
AT (1) | ATE524445T1 (de) |
AU (1) | AU2006262172B2 (de) |
CA (1) | CA2611530C (de) |
DK (1) | DK1896421T3 (de) |
HR (1) | HRP20110804T1 (de) |
RU (1) | RU2408584C2 (de) |
SI (1) | SI1896421T1 (de) |
WO (1) | WO2007002254A2 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1896421T3 (da) | 2005-06-23 | 2012-01-09 | Merck Sharp & Dohme | Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET |
CA2624676A1 (en) | 2005-10-21 | 2007-05-03 | Jongwon Lim | Tyrosine kinase inhibitors |
TW200813021A (en) * | 2006-07-10 | 2008-03-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
US8754094B2 (en) * | 2007-08-15 | 2014-06-17 | The Research Foundation Of State University Of New York | Methods for heat shock protein dependent cancer treatment |
US7893081B2 (en) | 2007-12-20 | 2011-02-22 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
AU2010300930B2 (en) | 2009-09-30 | 2014-09-11 | Merck Sharp & Dohme (Uk) Limited | Crystalline hydrochloride salts of c-MET kinase inhibitors |
US9238571B2 (en) | 2009-09-30 | 2016-01-19 | Merck Sharp & Dohme Limited | Formulations for c-Met kinase inhibitors |
CA2782146A1 (en) * | 2009-11-30 | 2011-06-03 | Proteologics, Ltd. | Small pyrimidine derivatives and methods of use thereof |
CN101857594B (zh) * | 2010-06-18 | 2013-04-03 | 南方医科大学 | 一种四氢吡啶并吲哚类化合物及其制备方法和应用 |
US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
EP2727920B1 (de) | 2011-07-29 | 2016-11-02 | FUJIFILM Corporation | 1,5-naphthyridin-derivat oder salz davon |
WO2013131089A2 (en) | 2012-03-02 | 2013-09-06 | The Board Of Trustees Of The University Of Illinois | Potent anticancer activity via dual compound activation |
ES2646008T3 (es) | 2012-03-06 | 2017-12-11 | The Board Of Trustees Of The University Of Illinois | Terapia combinada de procaspasa para el tratamiento del cáncer |
MX365392B (es) | 2012-03-06 | 2019-05-31 | Univ Illinois | Composición de combinación de pac-1 y doxorrubicina. |
EP2872161B1 (de) | 2012-06-26 | 2020-12-16 | Del Mar Pharmaceuticals | Dianhydrogalactitol zur verwendung bei der behandlung von tyrosinkinaseinhibitor-resistenten malignomen bei patienten mit genetischen polymorphismen oder ahi1-dysregulierungen oder mutationen |
WO2014150996A1 (en) * | 2013-03-15 | 2014-09-25 | Cba Pharma, Inc. | Cancer treatment |
EP2983674A4 (de) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutischer nutzen suboptimal verabreichter chemischer verbindungen |
US10398774B2 (en) | 2014-12-09 | 2019-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against AXL |
US9375419B1 (en) * | 2014-12-10 | 2016-06-28 | Southern Research Institute | Antiviral agents |
WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
WO2017161004A1 (en) * | 2016-03-15 | 2017-09-21 | University Of South Florida | PKCδ INHIBITOR FORMULATIONS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS |
WO2019099873A1 (en) | 2017-11-17 | 2019-05-23 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual mek signaling |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL132137C (de) | 1963-04-24 | |||
US4826853A (en) | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
JP2852659B2 (ja) | 1988-03-03 | 1999-02-03 | 富山化学工業株式会社 | ピペラジン誘導体およびその塩 |
ZA914764B (en) | 1990-06-22 | 1992-03-25 | Schering Corp | Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use |
US6365588B1 (en) | 1993-10-15 | 2002-04-02 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
ATE201195T1 (de) | 1995-10-16 | 2001-06-15 | Kyowa Hakko Kogyo Kk | Tricyclische verbindungen |
WO1998011097A1 (en) | 1996-09-13 | 1998-03-19 | Schering Corporation | Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein transferase |
KR20000036059A (ko) | 1996-09-13 | 2000-06-26 | 둘락 노먼 씨. | G-단백질 기능의 억제 및 증식성 질환의 치료에 유용한트리사이클릭 화합물 |
EP1251840A2 (de) * | 2000-01-26 | 2002-10-30 | Cedars-Sinai Medical Center | Verwendung von kaliumkanalaktivatoren zur verabreichung von medikamenten an anormalen gehirnregionen und/oder bösartigen tumoren |
US7018979B1 (en) | 2000-01-26 | 2006-03-28 | Cedars-Sinai Medical Center | Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor |
EP1427706B1 (de) | 2001-09-19 | 2007-05-30 | Pharmacia Corporation | Substituierte pyrazoloverbindungen zur behandlung von entzündungen |
WO2003084931A1 (en) | 2002-04-02 | 2003-10-16 | Merck & Co., Inc. | 5h-benzo[4,5]cyclohepta[1,2-b]pyridine nmda/nr2b antagonists |
ES2211315B1 (es) | 2002-11-12 | 2005-10-16 | Almirall Prodesfarma, S.A. | Nuevos compuestos triciclicos. |
JP2006151809A (ja) | 2002-12-26 | 2006-06-15 | Ube Ind Ltd | ベンゾシクロヘプタピリジン化合物 |
DK1896421T3 (da) | 2005-06-23 | 2012-01-09 | Merck Sharp & Dohme | Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET |
AU2006306517A1 (en) | 2005-10-21 | 2007-05-03 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
CA2624676A1 (en) | 2005-10-21 | 2007-05-03 | Jongwon Lim | Tyrosine kinase inhibitors |
JP2009513580A (ja) | 2005-10-21 | 2009-04-02 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
TW200813021A (en) | 2006-07-10 | 2008-03-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
-
2006
- 2006-06-22 DK DK06785313.5T patent/DK1896421T3/da active
- 2006-06-22 US US11/921,350 patent/US8207186B2/en active Active
- 2006-06-22 JP JP2008506834A patent/JP4119478B1/ja active Active
- 2006-06-22 AT AT06785313T patent/ATE524445T1/de not_active IP Right Cessation
- 2006-06-22 WO PCT/US2006/024247 patent/WO2007002254A2/en active Application Filing
- 2006-06-22 AU AU2006262172A patent/AU2006262172B2/en active Active
- 2006-06-22 US US11/473,273 patent/US7550478B2/en active Active
- 2006-06-22 SI SI200631207T patent/SI1896421T1/sl unknown
- 2006-06-22 RU RU2008102381/04A patent/RU2408584C2/ru not_active IP Right Cessation
- 2006-06-22 EP EP06785313A patent/EP1896421B1/de active Active
- 2006-06-22 CA CA2611530A patent/CA2611530C/en active Active
-
2007
- 2007-10-15 JP JP2007267377A patent/JP5086762B2/ja active Active
-
2011
- 2011-11-02 HR HR20110804T patent/HRP20110804T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CA2611530A1 (en) | 2007-01-04 |
RU2408584C2 (ru) | 2011-01-10 |
SI1896421T1 (sl) | 2012-01-31 |
WO2007002254A3 (en) | 2007-05-18 |
JP4119478B1 (ja) | 2008-07-16 |
US7550478B2 (en) | 2009-06-23 |
DK1896421T3 (da) | 2012-01-09 |
HRP20110804T1 (hr) | 2011-11-30 |
AU2006262172B2 (en) | 2010-05-27 |
CA2611530C (en) | 2012-11-20 |
WO2007002254A2 (en) | 2007-01-04 |
JP5086762B2 (ja) | 2012-11-28 |
RU2008102381A (ru) | 2009-07-27 |
US20060293358A1 (en) | 2006-12-28 |
AU2006262172A1 (en) | 2007-01-04 |
EP1896421A2 (de) | 2008-03-12 |
JP2008156336A (ja) | 2008-07-10 |
US8207186B2 (en) | 2012-06-26 |
EP1896421B1 (de) | 2011-09-14 |
US20090197908A1 (en) | 2009-08-06 |
JP2008536877A (ja) | 2008-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE524445T1 (de) | Benzocycloheptapyridine als inhibitoren der tyrosinkinase met | |
WO2008008310A3 (en) | Tyrosine kinase inhibitors | |
WO2007149427A3 (en) | Tyrosine kinase inhibitors | |
TW200738638A (en) | Tyrosine kinase inhibitors | |
WO2006124354A3 (en) | Tyrosine kinase inhibitors | |
ATE446094T1 (de) | Mitotische kinesin-hemmer | |
ATE424388T1 (de) | Mitotische kinesinhemmer | |
ATE447577T1 (de) | Mitotische kinesin-hemmer | |
CY1108927T1 (el) | Αναστολεις μιτωτικης κινεσινης | |
MX2007014616A (es) | Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos. | |
DE60329990D1 (de) | Mitotische kinesin-hemmer | |
ATE372341T1 (de) | Inhibitoren von mitotischem kinesin | |
WO2006086358A3 (en) | Mitotic kinesin inhibitors | |
WO2007050380A3 (en) | Tyrosine kinase inhibitors | |
WO2006078598A3 (en) | Mitotic kinesin inhibitors | |
NO20070589L (no) | Mitotiske kinesin-inhibitorer. | |
WO2007050383A3 (en) | Tyrosine kinase inhibitors | |
WO2007050401A3 (en) | Tyrosine kinase inhibitors | |
WO2006023440A3 (en) | Mitotic kinesin inhibitors | |
WO2006101761A3 (en) | Mitotic kinesin inhibitors | |
ATE426605T1 (de) | Inhibitoren von mitotischem kinesin | |
DOP2009000004A (es) | Inhibidores de tirosina quinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |